Who owns Inhibrx Biosciences, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of INBX from SEC Form 13F filings across 173 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 173 institutions disclosed 14.5M shares of Inhibrx Biosciences, Inc. worth $1.38B — about 92% of shares outstanding; the largest disclosed holder is MORGAN STANLEY. Source: SEC Form 13F filings, parsed by EvidInvest.
173
13F holders
$1.38B
value, 2026 filers
92%
of shares outstanding (14.5M sh)
41
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of INBX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 1.3M | $132.2M | 0.0% | 8.4% | +1.0% |
| 2 | PERCEPTIVE ADVISORS LLC | 1.3M | $129.3M | 2.3% | 8.2% | -0.4% |
| 3 | Sanofi | 1.2M | $115.9M | 18.4% | 7.4% | 0.0% |
| 4 | VIKING GLOBAL INVESTORS LP | 1.1M | $110.9M | 0.3% | 7% | -1.4% |
| 5 | HighTower Advisors, LLC | 884,441 | $88.5M | 0.1% | 5.6% | +1.6% |
| 6 | Schonfeld Strategic Advisors LLC | 827,280 | $82.8M | 0.3% | 5.3% | +18.6% |
| 7 | BlackRock, Inc. | 821,926 | $82.3M | 0.0% | 5.2% | -0.5% |
| 8 | TIG Advisors, LLCNEW | 677,789 | $508,342 | 0.0% | 4.3% | new |
| 9 | STATE STREET CORP | 565,749 | $56.6M | 0.0% | 3.6% | -11.7% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 537,262 | $53.8M | 0.0% | 3.4% | +9.1% |
| 11 | Woodline Partners LP | 400,892 | $40.1M | 0.1% | 2.6% | 0.0% |
| 12 | Sofinnova Investments, Inc. | 391,621 | $39.2M | 1.7% | 2.5% | +29.2% |
| 13 | Capital Research Global Investors | 362,466 | $36.3M | 0.0% | 2.3% | -0.2% |
| 14 | Parkman Healthcare Partners LLC | 360,260 | $36.1M | 3.2% | 2.3% | +40.2% |
| 15 | PFM Health Sciences, LP | 320,331 | $32.1M | 3.2% | 2% | +3.9% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 255,317 | $25.6M | 0.0% | 1.6% | -0.3% |
| 17 | GOLDMAN SACHS GROUP INC | 221,687 | $22.2M | 0.0% | 1.4% | -34.4% |
| 18 | Soleus Capital Management, L.P.NEW | 210,000 | $21.0M | 0.7% | 1.3% | new |
| 19 | First Turn Management, LLC | 171,512 | $17.2M | 2.3% | 1.1% | +4.1% |
| 20 | Trails Edge Capital Partners, LPNEW | 170,000 | $17.0M | 2.4% | 1.1% | new |
| 21 | CITIGROUP INC | 164,324 | $16.4M | 0.0% | 1% | +117.0% |
| 22 | CDC Financial, Inc. | 132,290 | $13.2M | 6.3% | 0.8% | -5.6% |
| 23 | FIRST TRUST ADVISORS LP | 126,651 | $12.7M | 0.0% | 0.8% | -1.4% |
| 24 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 119,200 | $11.9M | 0.1% | 0.8% | 0.0% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 112,157 | $11.2M | 0.0% | 0.7% | -8.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.